Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Genocea Biosciences stock | 2.06

Own Genocea Biosciences stock in just a few minutes.


Fact checked

Genocea Biosciences, Inc is a biotechnology business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 59 staff and has a trailing 12-month revenue of around USD$906,000.

How to buy shares in Genocea Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Genocea Biosciences. Find the stock by name or ticker symbol: GNCA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Genocea Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.06, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Genocea Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Genocea Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Genocea Biosciences's share price?

Since the stock market crash in March caused by coronavirus, Genocea Biosciences's share price has had significant negative movement.

Its last market close was USD$2.06, which is 3.74% down on its pre-crash value of USD$2.14 and 87.27% up on the lowest point reached during the March crash when the shares fell as low as USD$1.1.

If you had bought USD$1,000 worth of Genocea Biosciences shares at the start of February 2020, those shares would have been worth USD$699.03 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,000.01.

Genocea Biosciences share price

Use our graph to track the performance of GNCA stocks over time.

Genocea Biosciences shares at a glance

Information last updated 2020-10-20.
Latest market close USD$2.06
52-week range USD$1.1 - USD$5.75
50-day moving average USD$2.384
200-day moving average USD$2.4782
Wall St. target price USD$9.4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.376

Buy Genocea Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Genocea Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Genocea Biosciences price performance over time

Historical closes compared with the close of $2.06 from 2020-11-16

1 week (2020-11-23) -1.90%
1 month (2020-10-30) -0.96%
3 months (2020-08-28) -11.21%
6 months (2020-05-29) -25.36%
1 year (2019-11-29) -17.60%
2 years (2018-11-30) 227.09%
3 years (2017-11-30) 68.85%
5 years (2015-11-30) -67.81%

Genocea Biosciences financials

Revenue TTM USD$906,000
Gross profit TTM USD$-26,952,000
Return on assets TTM -49.41%
Return on equity TTM -176.71%
Profit margin 0%
Book value $0.245
Market capitalisation USD$131.5 million

TTM: trailing 12 months

Shorting Genocea Biosciences shares

There are currently 1.7 million Genocea Biosciences shares held short by investors – that's known as Genocea Biosciences's "short interest". This figure is 46.1% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting Genocea Biosciences shares can be evaluated.

Genocea Biosciences's "short interest ratio" (SIR)

Genocea Biosciences's "short interest ratio" (SIR) is the quantity of Genocea Biosciences shares currently shorted divided by the average quantity of Genocea Biosciences shares traded daily (recently around 512736.07038123). Genocea Biosciences's SIR currently stands at 3.41. In other words for every 100,000 Genocea Biosciences shares traded daily on the market, roughly 3410 shares are currently held short.

However Genocea Biosciences's short interest can also be evaluated against the total number of Genocea Biosciences shares, or, against the total number of tradable Genocea Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genocea Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Genocea Biosciences shares in existence, roughly 30 shares are currently held short) or 0.043% of the tradable shares (for every 100,000 tradable Genocea Biosciences shares, roughly 43 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genocea Biosciences.

Find out more about how you can short Genocea Biosciences stock.

Genocea Biosciences share dividends

We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.

Have Genocea Biosciences's shares ever split?

Genocea Biosciences's shares were split on a 1:8 basis on 22 May 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.

Genocea Biosciences share price volatility

Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $1.1 up to $5.75. A popular way to gauge a stock's volatility is its "beta".

GNCA.US volatility(beta: 2.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 2.15. This would suggest that Genocea Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Genocea Biosciences overview

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site